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Abstract  
Neurodegenerative diseases (NDDs) represent a huge social burden, particularly in the 
Alzheimer’s disease (AD) in which all proposed treatments investigated in murine models 
have failed during clinical trials. Thus, novel therapeutic strategies remain crucial. 
Neuroinflammation is a common pathogenic feature of all NDDs. As purinergic P2X7 
receptors (P2X7Rs) are gatekeepers of inflammation, they could be developed as drug 
targets for NDDs. Herein, we review this challenging hypothesis, and comment on the 
numerous studies that have investigated P2X7Rs, emphasizing their molecular structure 
and functions, as well as their role in inflammation. Then, we elaborate on research 
undertaken in the field of medicinal chemistry to determine potential P2X7R antagonists. 
Subsequently, we review the state of neuroinflammation and P2X7R expression in the 
brain, in animal models and patients suffering from AD, Parkinson’s disease, 
amyotrophic lateral sclerosis, Huntington’s disease, multiple sclerosis, and retinal 
degeneration. Next, we summarize the in vivo studies aimed at testing the hypothesis that 
by mitigating neuroinflammation, P2X7R blockers afford neuroprotection, increasing 
neuroplasticity and neuronal repair in animal models of NDDs. Finally, we reviewed 
previous and ongoing clinical trials investigating a plethora of compounds directed 
toward diverse targets associated with NDDs; we propose that clinical trials with P2X7R 
antagonists should be initiated. Despite the high expectations for putative P2X7Rs 
antagonists in various central nervous system diseases, the field is moving forward at a 
relatively slow pace, presumably due to the complexity of P2X7Rs. A better 
pharmacological approach to combat NDDs would be a dual strategy, combining P2X7R 
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1 INTRODUCTION 
Brain diseases affect one billion individuals worldwide, representing an economic burden 
higher than cancer and cardiovascular diseases combined. In Europe alone, 179 million 
neuropsychiatric patients represent 35% of the burden associated with all diseases, 
estimated at an annual cost of 800 billion euros.1 The increased suffering observed in 
these patients is frequently associated with serious co-morbidities, multiplying the costs 
associated with non-medical care i.e. nursing homes, as well as indirect costs such as 
nonattendance at the workplace.2 As NDDs are age-dependent, increasing longevity will 
progressively augment their prevalence and hence, the socio-economic burden. 
Despite diverse symptomatology and pathophysiology, cumulative evidence suggests that 
neuroinflammation holds the central stage in NDDs, including Alzheimer’s disease (AD), 
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease 
(HD), multiple sclerosis (MS), and retinal degeneration. Currently, treatments available 
for these disorders are merely symptomatic; hence, novel brain-permeable drugs are 
urgently needed to reduce disease progression. As purinergic P2X7 receptors (P2X7Rs) 
are considered gatekeepers of neuroinflammation, it is explicable that both academic and 
pharmaceutical research remain involved in drug development programs focused on the 
discovery of P2X7R antagonists with therapeutic potential in brain diseases.3 
Here, we comprehensively review this hot topic, first presenting a concise account of 
P2X7Rs and purinergic signaling. Then, we highlight the molecular structure and 
function of P2X7Rs, emphasizing their role in inflammation. Next, we detail the 
molecular and pharmacokinetic aspects of different groups of P2X7Rs antagonists 
synthesized to date. Moreover, we comment on the contribution of P2X7Rs and 
neuroinflammation in association with the pathogenesis of NDDs, in both animal models 
and patients suffering from NDDs. Finally, we address the proof-of-concept of the 
therapeutic potential of P2X7R antagonists in animal models of NDDs, concluding with 




2 PURINERGIC RECEPTORS AND PURINERGIC SIGNALING 
Almost 50 years have passed since Geoffrey Burnstock unveiled “the purinergic nerves” 
as nerves that could be stimulated by a neurotransmitter distinct from acetylcholine (ACh) 
and catecholamines, namely adenosine triphosphate (ATP).4-6 We are now aware that 
ATP performs its functions by acting on specific receptors expressed in immune cells, 
blood cells, dendritic cells, vascular smooth muscle cells, secretory cells, neuronal cells, 
as well as retinal cells. These receptors are divided into two classes depending on their 
predominant endogenous agonist: P1 receptors are activated by adenosine (ADO), while 
P2 receptors are activated by purine and pyrimidine nucleotides, mainly ATP and 
adenosine diphosphate (ADP). 
P2 receptors are further classified into two groups: P2Y and P2X receptors. The former 
are metabotropic receptors and the latter are ligand-gated ion channels. They are homo- 
or heterotrimers with seven characterized subunits (P2X1-7), composed of two α-helical 
transmembrane domains (TM), a short intracellular N-terminal, a C-terminal more 
variable in length, and a large extracellular loop of 269-288 amino acids, mostly folded 
as β-sheets and loops.7. Depending on their distinct activation and desensitization 
kinetics, P2XRs are classified into three main groups. On one hand, P2X1 and P2X3 
homomers are activated in the range of milliseconds and rapidly desensitize; on the other 
hand, the remaining subtypes are rapidly activated in approximately a second but can 
undergo slow desensitization or no desensitization. P2X4, P2X4/6, P2X2/3, and P2X2/6 
receptors are slowly desensitized, while P2X5, P2X7, and P2X1/5 receptors present a 
persistent plateau in current during prolonged ATP applications.8,9. Except for the P2X5R 
which is Cl- permeable, the other P2XRs allow Na+ and Ca2+ influx and K+ efflux, 
following their electrochemical gradient through the plasmalemma.  
Notably, a high number of purinergic receptors have been identified, along with a rich 
system of enzymes capable of hydrolyzing endogenous ATP to adenosine, ADP or other 
active metabolites, thus clarifying the significance of modulating this signaling system in 
different physiological and pathological processes.10-12 Furthermore, it has been 
demonstrated that these receptors are involved in cell homeostasis, degeneration and 
regeneration of neurons13 and retinal cells,14 cell proliferation and tumor growth,15 
immune disorders and inflammation,16-18 thrombosis,19 viral infections and replication,20 




neurodegenerative and neuropsychiatric diseases.24-28 Table 1 summarizes the subtypes 





3 P2X7 RECEPTORS 
Over the past 50 years, researchers have demonstrated the activation of a growing number 
of cell types in almost all vertebrate tissues mediated by extracellular ATP. Response-
eliciting ATP concentrations ([ATP]e) were predominantly in the low µM range; 
however, in some cells such as macrophages and mast cells, hundreds of µM [ATP]e 
caused a distinct pattern of activation, consisting of  Ca2+ influx and membrane 
“permeabilization” to fluorescent dyes up to approximately 1 kDa  29-32. This response 
was attributed to a specific type of membrane receptors of the purinergic type, initially 
labeled P2Z 33, and later identified as P2X7 receptors 34. In the 1990s, P2Z/P2X7 
activation was involved in the release of interleukin (IL)-1β, as well as macrophage 
communication and differentiation 35-37. F. Di Virgilio integrated the above research with 
the fact that the receptor was mainly expressed in immune lineage cells, proposing the 
currently accepted hypothesis that the physiological role of the P2X7 receptor was to 
mediate chronic inflammatory responses 38,39.  
 
3.1 Molecular structure and function of P2X7 receptors  
The P2X7R is a non-selective ligand-gated ion channel permeable to Na+, Ca2+, and K+, 
which assembles as homotrimers. Some studies suggested that it could form heterotrimers 
with P2X4 subunits;40,41 however, this hypothesis remains controversial, considering that 
no physical evidence of P2X4/P2X7 heterotrimers has been obtained (e.g. through cross-
linking or blue native PAGE studies) in overexpressing systems or native tissue.42-44. 
Using alternative splicing and single-nucleotide polymorphisms (SNPs), various 
conformational changes of the receptor resulted in enhanced or inhibited activity.45 This 




which also contains a lipopolysaccharide (LPS)-binding domain, modulating LPS-
triggered intracellular signal transduction.46 The recently revealed rat P2X7R structure 
presented a dinuclear zinc-ion complex and a guanosine nucleotide-binding site in the C-
terminal domain. These sites do not influence receptor gating and future studies are 
needed to determine their involvement in P2X7R signal transduction modulation.47. The 
P2X7R exhibits low affinity for ATP and is permeable to small molecules up to 900 Da 
in molecular weight.34 This feature seems to be attributed to distinct characteristics of its 
ATP binding pocket, which lacks four amino acids with respect to other subtypes and is 
characterized by more hindered and hydrophobic residues.48,49 This results in a narrower 
pocket less likely to be exposed to the solvent, and consequently more inclined to 
structural fluctuation, decreasing ATP accessibility47, according to the pocket breathing 
motion model discussed by Stank et al. 50. 
Several natural splice variants (P2X7A-J) were discovered in human and rodent tissues; 
P2X7A is the well-characterized full-length P2X7R. The P2X7B isoform is particularly 
relevant owing to its sequence similarity with other P2X receptors, a wide tissue 
distribution, and a lack of the proapoptotic P2X7A actions 51,52. This suggests that P2X7R 
responses could be finely tuned by the expression of various P2X7R isoforms. Moreover, 
this has been elegantly illustrated in a recent study: transfection of P2X7B augmented 
NFATcl activation, enhanced ATP content, and supported cell growth; however, the 
transfected cells failed to undergo ATP-triggered apoptosis. Additionally, P2X7B was 
shown to co-assemble with P2X7A forming a P2X7A+B heterotrimer directly modulating 
its functions, including pore formation. An interesting hypothesis suggested that P2X7A 
receptors could be considered the “deadly” molecular evolution of an otherwise harmless 
P2X7B receptor 53. Thus, P2X7B is capable of forming functional channels, but not the 
large pores frequently associated with inflammation and cell death 53. 
P2X7K54 is fully functional in mice, with an 8-fold higher sensitivity to agonists, slower 
deactivation, and augmented ability to form pores than the human variant. Additionally, 
nicotinamide adenine dinucleotide (NAD) activated the P2X7K isoform; however, it 
remained unable to activate P2X7A55. In this study, P2X7A was preferentially expressed 
by macrophages and P2X7K was expressed in T cells. In rodents, this could give rise to 
differences in P2X7R signaling between different cell types56,57. The influence of these 
and other variants on P2X7R signaling, both in vitro and in vivo, could present a 




the difference in sensitivity of these variants to P2X7R antagonists being investigated 
could be relevant, as well as the extrapolation of these outcomes to clinical trials in 
humans. Moreover, approximately 150 nonsynonymous (or missense) SNPs, with altered 
human P2X7Rs functions, further complicate an already complex situation 58-60. 
To date, no crystal structure of the human receptor (hP2X7R) has been demonstrated by 
co-crystallization with ATP, neither in the apo-state nor the active state. Nevertheless, 
receptor activation and inhibition mechanisms were first investigated through homology 
modeling, by utilizing an already existing hP2X3R and zebrafish P2X4R (zfP2X4R), and 
more recently through the crystallization of the giant panda (Ailuropoda melanoleuca) 
ortholog (85 % of identity with the human receptor) in its apo-state, or along with several 
antagonists.49,61 In these studies, each P2X7 subunit demonstrated the typical conserved 
dolphin-like structure, composed of the head domain (HD), the upper body (UB), the 
lower body (LB), the dorsal fin (DF), the left and right flippers (LF and RF, respectively), 
and the fluke (F). ATP, in its free ion form, binds to the so-called “binding jaws”, located 




ATP adopts a U-shaped conformation upon binding through the interaction of phosphates 
with the adenine base, similar to the ATP interaction with class II aminoacyl transfer 
RNA synthetases. However, when ATP binds to other proteins, the preferred 
conformation is stretched.62 During activation, the UB subunit shrinks toward the central 
axis of the receptor, leading the LB to broaden, forming fenestrations allowing the 
passage of ions through a lateral pathway, away from the central axis. These 
conformational changes result in a vertical stretch and rotation of the two TM domains, 
thus opening the channel gate. A structural characteristic of the P2X7R is an extracellular 
pocket located internally at the top of the UB, which is wider than in other family 
subtypes. This is the allosteric binding site for several antagonists, as demonstrated by 
the crystallized panda P2X7R and in subsequent mutagenesis and molecular docking 




Finally, P2X7Rs sensitivity to ATP differs between species. In detail, ATP has a higher 
pEC50 in rat P2X7R than in mouse and human orthologs (3.4±0.10 against 2.7±0.07 and 
2.8±0.06, respectively), demonstrating lower efficacy. Furthermore, these differences are 
evident when the more potent benzoylbenzoyl-ATP (BzATP) is used as an agonist 
(pEC50: 5.2±0.09 for rat, <3.5 for mouse, and 4.1±0.06 for human P2X7R) 
64 and can be 
correlated with dissimilarities in current kinetics. In stably transfected HEK293 cells, 
measured rat P2X7R currents revealed a higher decay time than other orthologs under 
BzATP stimulation. This depended on agonist association and dissociation rates, 
determined by protein-ligand interactions, implying that structural differences among 
species are responsible for these observations64. Notably, Young et al. demonstrated that 
mouse P2X7R sensitivity for ATP and BzATP approached that of the rat when mouse 
aspartate 284 and alanine 127 were converted into the corresponding rat amino acids at 
these positions, asparagine and lysine (i.e. D284N and A127K mutations) 65. 
Additionally, these differences in ligand potency were observed for several allosteric 
modulators. For instance, AZ11645373 is a potent antagonist of human and dog P2X7Rs 
at nanomolar concentrations, active only at µM concentrations in mouse orthologs and 
inactive in rats66. These differences were attributed to amino acid 95, which is 
phenylalanine in human P2X7R and can form a pi-stacking interaction with AZ11645373, 
differing from leucine 95 in rat orthologs.66,67. Another example of species-dependent 
differences is reportedly the pharmacological activity of GW791343, a potent P2X7 
antagonist in humans, but a positive allosteric modulator in rats 68. 
 
3.2 The P2X7 receptor as a gatekeeper of inflammation 
A recent review by Francesco Di Virgilio and coworkers addressed the role of P2X7R as 
the main player in inflammation.39 This is understandable considering that P2X7Rs are 
expressed by immune and inflammatory cells and are upregulated in inflammatory 
processes, including dendritic cells, osteoclasts, and microglia, the most widely studied 
cells from the monocyte/macrophage axis. Additionally, P2X7Rs are expressed by mast 
cells, NK cells, and T and B lymphocytes.69 
Cell components including ATP are released into the extracellular space as a result of 
stress or tissue damage (danger-associated molecular pattern, DAMP), inducing the 




recognized that P2X7Rs are the main sensor for high concentrations of ATP during 
inflammation, as the concentration required to activate them (EC50=100 μM) is one or 
two orders in magnitude than for other P2XRs70, demonstrated under conditions of stress 
and tissue damage. Additionally, P2X7Rs are the main trigger of the immune response 
by mediating the maturation and secretion of several interleukins, mainly IL-1.71,72 The 
maturation of IL-1 requires the activation of the NLRP3 inflammasome by ATP-
dependent K+ efflux.72-75 This intracellular K+ drop is possibly the best-established 
mechanism underlying P2X7R-mediated formation of the NLRP3 inflammasome.76  
Ion fluxes are critical events in NLRP3 inflammasome activation. For example, various 
inflammasome activators, including ATP, nigericin, and particulate or crystalline 
molecules, induce K+ efflux and a concomitant decrease in its intracellular 
concentration76,77. Additionally, Na+ influx accompanied by water influx diminishes the 
cytosolic K+ concentration below the threshold, leading to inflammasome activation78. 
Notably, reactive oxygen species (ROS) induce inflammasome aggregation and IL-1 
release, secondary to P2X7R activation.79,80 Additionally, protein-protein interactions 
between P2X7Rs and the inflammasome scaffold occur in astrocytes, where they mediate 
IL-1 maturation and release;81 this also occurs at restricted subplasmalemmal areas of 
microglia and macrophages.82 The synthesis of immature pro-IL-1 occurs through a 
process requiring the activation of the nuclear factor kappa B (NF-κB) . In turn, 
maturation of IL-1 requires cleavage by caspase-1 (Casp-1), matured and activated via 
inflammasome formation.83,84 This cascade ends with IL-1 release into the extracellular 
space through non-classical transport mechanisms,85 finally triggering inflammatory 
processes (Figure 2). 
P2X7Rs have been associated with various neurological disorders exhibiting pathogenic 
inflammatory features. Indeed, these receptors are expressed by several brain cell types, 
including astrocytes, microglia, oligodendrocytes, and Schwan cells.86 However, whether 
P2X7Rs are additionally expressed in neurons currently remains controversial.87,88 In 
Section 5.1 we will further comment on evidence suggesting that P2X7Rs and 







4 P2X7R ANTAGONISTS: MOLECULAR STRUCTURE AND DRUG-
LIKENESS 
Initial attempts to synthesize P2X7R ligands were demonstrated in nucleotide analogs 
with broad-spectrum anti-purinergic receptor activity, including the covalently bound, 
irreversibly oxidized ATP (oATP) (Figure 3),89 found to attenuate pro-inflammatory 
signals via P2 receptor-independent mechanisms.90 Other frequently used 
pharmacological tools include the non-selective competitive P2X7R antagonist pyridoxal 
phosphate derivative PPADS,91, as well as the non-competitive triphenylmethane dye, 
Brilliant Blue G (BBG),63,92 the naphthylsulfonate suramin and its isoquinoline 
derivative, KN-62,93 also known for inhibiting CaM kinase II (Figure 3). BBG has been 
utilized in both in vitro and in vivo experiments; however, this compound also targets 
P2X4, P2X5, rat P2Y1, and P2Y2 receptors, as well as voltage-gated sodium 
channels.8,94,95 BBG was initially the main compound used for the proof-of-concept of 
P2X7Rs role in NDDs, such as ALS and AD.96-98 Its permeability across the blood-brain 
barrier (BBB) remains dubious as it is a heavy and charged molecule;  however, BBG 
reaches central nervous system (CNS) damaged tissues probably through BBB disruption 
in animal models of NDDs. 99 During the discovery of novel ligands for P2X7Rs, interest 
shifted from peripheral disorders such as rheumatoid arthritis100,101 and Crohn’s 
disease,102 to pathologies of the CNS; this was reasonable considering the important role 
that P2X7Rs play in neuroinflammation and subsequently, in NDDs.16,103  
The search for more potent and selective P2X7R antagonists targeting the CNS with BBB 
permeable compounds led to the discovery of novel derivatives, including adamantane 
and o-chlorobenzamide moieties (1 – Figure 3).104,105 In this context, we will comment 
on second-generation compounds focused on reproducing P2X7R blockade, thereby 
blocking IL-1 release, and also on improving their pharmacokinetic properties for 
targeting CNS diseases. Notably, most work has been performed by Big Pharma, 
underlining the therapeutic relevance of P2X7Rs in implicated diseases. Despite some 
examples that could be considered “me-too” derivatives, each company has initiated 







Kim and coworkers discovered that some analogs of berberine alkaloids possessed 
hP2X7R blockade capacity. The chemical modifications proposed on hit compounds, in 
particular the alkyls and benzyl groups, gave rise to a set of quinazolinium derivatives 
with IC50s around 1 M, the most potent being the nitro-derivative 2 (IC50 = 0.17 nM, 2-
fold more potent than KN-62) (Figure 4).106 Additionally, this compound exhibited the 
highest potency to block LPS/interferon (IFN)-induced IL-1 release from THP-1 cells 
(IC50 = 175 nM). Another screening identified chiral pyrazolodiazepinones with some 
activity against hP2X7Rs expressed in HEK293 cells. This inhibition and related 
suppression of IL-1 release were improved following the incorporation of an N-
methylindole cycle, linked by an ester at the central core;107 this resulted in ligands with 
activity similar to KN-62, such as 3 (Figure 4). This second family of compounds was 
universally less potent than the former, lacking quaternary nitrogens, thereby increasing 
BBB permeability. More recently, investigators described a series of pyrimidine-2,4-
dione related to KN-62, possessing isoquinoline-5-sulfonate and phenylpiperazine 
moieties in their structure.108 Substitution at the pending phenyl ring, as well as the 
presence or absence of a spacer (methyl or carbonyl), conditioned the structure-activity 
relationship. For instance, benzoyl analogs with different halogen substitutions afforded 
the best inhibition, as in the case of derivative 4, which was superior to KN-62 (Figure 
4). Furthermore, several researchers demonstrated that the piperazine substructure well 
accepted other acyl groups of hydrophobic nature (alicyclic or cyclic alkyls, such as 
adamantyl), offering similar blockade. Compound 4 was selected for investigating some 
of its pharmacokinetic (PK) parameters, presenting high metabolic stability and low 




Another approach involved a design based on N-benzylacetamide with halogen phenyl 
substitution (Figure 5). Moreover, different aryls and heterocycles were extensively 




poor in vitro stability. Most attempts to improve blockade and PK profile frequently 
focused on replacing halogens, the amide spacer, or the pyrazole ring. Removal of the 
phenyl at the pyrazole (R = H, Figure 5) was essential for enhancing both properties, 
resulting in ligands 6 (R = H, X = F)109 and 7 (R = H, X = Cl)110. Unfortunately, this 
additionally inhibited cytochrome P450 3A4 (CYP3A4); hence, researchers selected 
another hit, providing clues to modify the initial structure by replacing the pyrazole ring, 
possessing metabolically-labile methyl groups, with cyclic pyroglutamic amides, 
exemplified by 8 (Figure 5). This change avoided CYP inhibition while maintaining 
metabolic stability and marginally improving P2X7R blockade, as observed with 
compound 8111 (Figure 5). This compound was evaluated in animal models of pain but in 
some, its half-life was not as expected. Therefore, to eliminate metabolically-labile 
positions, pyroglutamic acid was again replaced by other heterocycles, demonstrating 
satisfactory outcomes with the imidazole moiety, as the IC50 of that family was in the 
nanomolar range. Furthermore, these compounds presented low microsomal clearance. 
Among these, the unsubstituted imidazolone 9 appeared to stand out112 (Figure 5). 
Based on the work investigating pyroglutamic acid derivatives, Ghinet and coworkers 
have recently described constrained analogs obtained as unexpected products (10 – Figure 
5) from the treatment of pyroglutamic acid lactams with the Bredereck’s reagent.113 
Despite their synthetic interest, none of the resulting pyrroloimidazolediones offered 
good P2X7R blocking activity and their intermediates, presenting a pyroglutamide 





An o-chlorobenzamide derivative, bearing a 1,2,4-triazine heterocycle, showed moderate 
P2X7R inhibitory activity and extremely high clog P (11) (Figure. 6). Theoretically, this 
property is compatible with high BBB permeability, an effect that entails low solubility, 
a drawback for drug development. Therefore, the program focused on improving the 
blocking activity by preparing compounds possessing a lower clog P.114 Based on an 




activity, the long hydrophobic chain bound to the amide nitrogen was replaced by bulky 
alkyl, aryl, or heteroaryl groups. In this work, the presence of (1-
hydroxycycloheptyl)methyl, as a substituent for the amide (12) (Figure 6), lowered clog 
P to 2.9, improving the potency to inhibit IL-1 release by 10-fold with respect compound 
11. Based on this replacement, clog P was further lowered by incorporating polar alkyl 
chains at the 1,2,4-triazine core, as shown in CE-224,535 (Figure 6). Additionally, the 
potency to block IL-1 release was 59-fold higher than that observed in 12 and 





Abbott Laboratories disclosed a series of cyanoguanidines with high potency and good 
pharmacokinetic properties. A-740003 (Figure 7) was the first to distinguish itself based 
on its high potency in the nanomolar range.115 In animal models of neuropathic pain, the 
compound attenuated tactile allodynia; however, a radiotracer study revealed its poor 
BBB permeability.116 Further modifications on this scaffold by retaining the isoquinoline-
cyanoguanidine moiety presented cyanoguanidine-piperazine P2X7R antagonists with 
slight differences in activity with respect A-740003 117. Substitution of the piperazine 
core with a simpler (R)-α-methylbenzylamine resulted in A-804598 (Figure 7), a ligand 
with an IC50 of approximately 10 nM in rat, mouse, and human P2X7R, as evaluated in 
calcium flux assays118. Furthermore, it proved certain stability in brain tissues, at least 
after 1 h of oral administration119. A-740003 and A-804598 have both been crystallized 
in the panda P2X7R, demonstrating that they bind in the allosteric binding pocket at the 
interface of the two subunits’ upper bodies 49. Moreover, they are considered the two 
P2X7R antagonists presenting the least potent differences between species 120. 
Kassiou and coworkers pursued the adamantane cycle to obtain drug-like P2X7R ligands. 
Thus, they improved the solubility of target ligands by including non-protic, highly polar 
moieties such as cyanoguanidine.121 A large set of differentially linked adamantane-
cyanoguanidine adducts was evaluated, where the 5-quinolyl derivative 13 (Figure 7) 




assessment, and was substituted by the more polar compound 14 (Figure 7), with 
improved PK properties, still far from ideal. In contrast, Kassiou and coworkers proposed 
derivatives of 1 (Figure 3), defined by either replacing the o-chlorobenzamide group by 
heteroaromatic analogs, such as pyridines or diazines, or replacing some adamantane 
hydrogens by fluorine atoms122 (Figure 7); this could be justified by the bioisosteric nature 
of these chemical modifications, which would presumably reduce lipophilicity and 
increase metabolic stability. However, although the experimentally obtained log D of the 
aza-analogs of 1 was slightly reduced, their hP2X7R blockade was potent, particularly 
for 15 (Figure 7). Regarding the fluorinated derivatives of 1 (Figure 3), the lipophilicity 
was substantially decreased and hP2X7R blocking activity remained in the same order of 
magnitude, implying an improvement in the ligand-lipophilicity efficiency. This 
promising success prompted the evaluation of their PK characteristics, such as stability 
in liver microsomes, permeability, and CYP inhibition, as well as P-glycoprotein (P-gp)- 
efflux. The trifluorinated 16 (Figure 7) exhibited the highest metabolic stability, 6-fold 
higher than 1, presenting the lowest CYP inhibition rate. Additionally, 16 demonstrated 
the highest bioavailability, as well as a prolonged brain half-life. All of these data revealed 
that 16 warranted further preclinical evaluation in models of CNS disorders where 
P2X7Rs have been implicated. 
FIGURE 7 
 
A new series of heterocyclic derivatives were linked to the o-chlorobenzamide moiety, 
and could be considered as a juxtaposition of JNJ-42253432 (Figure 8)123 and compound 
17124 (Figure 8). Position C2 of the quinoline demonstrated diverse alkylamines;125 their 
activity on P2X7Rs was scattered and differences between human and mouse orthologs 
were observed. Compound 18 was considered superior, bearing a 3-(R)-
hydroxypyrrolidine at C2 (Figure 8), which demonstrated good bioavailability and a 
significant, though time-dependent, reduction in IL-1ß release in C57BL/6 mice. 
Moreover, another member of this class of ligands, JNJ-47965567 (Figure 8), was 
pharmacologically characterized. In particular, it efficaciously reduced the sensitization 
of amphetamine-induced locomotion, without exhibiting robust results in models of 




47965567 is one of the antagonists crystallized in the panda P2X7R and its binding site 





Simultaneous to the development of these P2X7R ligands, investigators examined the 
triazolopiperidine scaffold, linked to the o-chlorobenzamide moiety (Figure 9). Initially, 
the influence of aza-aromatic ring substitution at the triazole was examined, as 
exemplified by 19127 (X = H, Figure 9). Aza-aromatics reduced both log P and CYP 
inhibition. Compound 19 was selected as the lead to be optimized by fixing its pyrimidine 
heterocycle at N1 and replacing the 3-trifluoromethyl-2-chlorophenyl by other 
halogenated benzenes. However, no significant improvements were obtained in PK 
values; additionally, in some cases, the potency was diminished, and the cross activity 
between orthologs deteriorated universally. Preclinical studies demonstrated that the 
incorporation of a fluorine atom (20, X = F, Figure 9) improved PK parameters such as 
bioavailability and solubility. Further studies aimed to evaluate the effect of an R-
methylation at the piperidine C4,128 with the intent of increasing microsomal metabolic 
stability and potency, like that previously appreciated in the P2X7R antagonist, JNJ-
54166060 (Figure 9); this compound has also demonstrated nanomolar P2X7R antagonist 
activity, as well as a good PK profile,129 but was affected by an unavoidable CYP3A 
interaction. Using an R-methylated 19 derivative at C4 as the scaffold, single aza-
aromatics were installed at N1 of the triazole nucleus, furnishing ligands with nanomolar-
ranged potency, highlighting the 4-(R)-methyl derivative 20 (JNJ-54175446 – Figure 9); 
this compound lacked CYP inhibition and demonstrated elevated metabolic stability, high 
bioavailability, and low off-target pharmacology. Further pharmacological experiments 
revealed high tolerability, resulting in compound JNJ-54175446 as a candidate for clinical 
studies. 
By shuffling the methyl group from C4 to C6 using configuration inversion, a new family 
of triazolopiperidines was revealed130 (Figure 9), presenting different aromatic N-




families, presenting low solubility and poor stability. To resolve these obstacles, 
benzamide was replaced with isonicotinamide, as shown in JNJ-55308942 (Figure 9). 
Solubility and metabolic stability were improved, but the activity was diminished. The 
para-fluor derivative was again the best of the family, demonstrating an increased plasma 
free fraction, high tolerability, and cardiovascular safety. Based on these findings, JNJ-
55308942 was selected as a second P2X7R antagonist to enter clinical trials for 
depression. Phase I ended in March 2018, evaluating the safety of the compound in 
healthy participants. In 2017, JNJ-54175446 (Figure 9) was tested in healthy volunteers 
and patients experiencing major depressive disorders131. Currently, it has entered phase 





Collectively, several P2X7R antagonists have been developed through the years, 
exploiting different scaffolds and molecular structures. Nevertheless, only a few ligands 
succeeded in entering clinical trials, and the majority of them in peripheral disorders.100,102 
This is attributed to poor knowledge of the hP2X7R structure, and primarily the lack of 
its crystal resolution, and additionally the need to discover proper drug-like properties to 
target the CNS, i.e. sufficient lipophilicity, water solubility, and brain tissue half-life. 
Hence, BigPharma pays considerable attention to assess receptor occupancy of the newly 
developed ligands, as well as their efficacy in the brain, by performing well-established 
ex vivo autoradiography assays or in vivo microdialysis in animals. Table 2 summarizes 









5.1 Neuroinflammation, a common pathogenic feature of NDDs 
Neuroinflammation is characterized by the presence of reactive astrocytes and microglia 
in the CNS. These cells, as well as peripheral immune cells and endothelial cells, produce 
pro-inflammatory cytokines (IL-1, IL-16, TNF-), chemokines (CCL2, CCL9, CCL1), 
ROS, and secondary messengers (NO, prostaglandins).132,133 
The duality of the neuroinflammatory status remains of interest, as glial cells may exhibit 
pro- and anti-inflammatory functions. Thus, a low-level of glial inflammation causes 
corticosteroid release, free radical reduction, phagocytosis, and cellular repair. This may 
support synaptic plasticity, as well as regulate learning and memory.134,135 Conversely, a 
high level of destructive neuroinflammation is observed, with a notable production of 
pro-inflammatory mediators, infiltration of peripheral immune cells, edema and 
augmented permeability of the BBB136-138, as observed in the case of acute CNS 
infections139 or stroke.140 
Between these two extreme cases, lies the concept of low-level glial cell activation, with 
low to moderate levels of inflammatory mediators present in the parenchyma of the brain 
or spinal cord in patients with NNDs; in the long term, this low inflammatory status leads 
to synaptic dysfunction, loss of synapses, and neuronal death.141 Furthermore, there exists 
an interesting hypothesis based on the fact that microglia have the same progenitor origin 
as macrophages.142 Glial cells exhibit a low overall turnover rate;143,144 this may explain 
why glial cells are susceptible to potential pro-inflammatory effects of age, injury, stress 
or NDDs.133 
In this context, investigations surrounding the neuroinflammatory status of NDDs have 
gained momentum during the last few years. Hence, imaging techniques such as positron 
emission tomography (PET) are being utilized to quantify the inflammatory status of the 
brain and spinal cord in patients with NDDs. This approach has assisted in identifying 
pathophysiological features of NDDs, as well as novel targets for the development of 
drugs that, by acting on neuroinflammatory pathways, could exhibit neuroprotective 
properties.145 We will next review the available evidence demonstrating the presence of 
neuroinflammation and its potential relationship with P2X7Rs, from preclinical in vitro 





However, results from preclinical studies using P2X7R knockout (KO) mice should be 
considered with caution. For instance,  KO strains from GlaxoSmithKline (GSK )146 or 
Pfizer 147 have been extensively used to explore the role of P2X7Rs in inflammatory and 
neuropathic pain (GSK KO), inflammation, cytokine production, bone formation and 
various disorders (Pfizer KO)148. However, the discovery of P2X7R splice variants 
suggests that these mice may not be true knockouts. 
For instance, a P2X7R variant escaped deletion in the GSK KO and demonstrated its 
highest expression in the spleen 54. Furthermore, the P2X7 13B and 13C C-terminal 
truncated variants escaped deletion in Pfizer KO mice 149. Moreover, in other studies, 
anti-P2X7R antibodies detected P2X7R in both mouse strains, although the P2X7A 
receptor was knocked out in these strains, thus suggesting that antibodies may be 
detecting splice variants that escaped deletion150,151. Therefore, caution is warranted with 
data interpretation from in vivo studies utilizing these KO mice. 
 
5.2 Alzheimer’s disease (AD) 
The involvement of P2X7R-induced neuroinflammatory responses in AD has been 
supported by in vitro and in vivo preclinical studies, as well as postmortem studies in the 
brain of AD patients. An early study demonstrated that two P2X7R agonists, namely ATP 
and the more specific BzATP, enhanced [Ca2+]c and H2O2 production in rat microglia. 
These in vitro effects were blocked by three P2X7R antagonists, oATP, BBG, and 
PPADS. Furthermore, interestingly, ATP and BzATP elicited neuronal death in glia-
neuron co-cultures.152 
In microglia and THP-1 cells, enhanced Ca2+ entry triggered by stimulation with BzATP 
produced an inflammatory response by enhancing p38 MAP kinase and NF-B, with 
concomitant release of IL-6, TNF- and nitrite ions neurotoxic to SH-SY5Y cells. These 
effects were ameliorated by Mg2+ and the P2X7R antagonists oATP and KN-62. 
Investigators have suggested that Mg2+ could reduce Ca2+ induced neuroinflammation in 
AD.153 
Microglia activation by A requires P2X7R expression as demonstrated in experiments 
by Francesco Di Virgilio and coworkers, demonstrating that in microglia from wild type 




permeability; these effects were not observed in microglia from P2X7R-deficient mice, 
suggesting that microglial activation requires the presence of P2X7Rs.154 Additionally, 
silencing of P2X7Rs augmented microglial phagocytosis induced by A155 A more 
recent study showed that P2X7R overexpression induced by A oligomers, augmented 
synaptic failure and neuronal dyshomeostasis in cellular models of AD.156 Additionally, 
a paradoxical neuroprotective effect of P2X7R stimulation has been reported.152 
Moreover, P2X7R stimulation causes the activation of the soluble APP ectodomain 
(sAPP) from mouse neuroblastoma cells, expressing human APP, as well as from human 
neuroblastoma cells, mouse astrocytes, or neural progenitor cells. This effect was not 
observed in P2X7R-deficient mice.157 
Furthermore, some in vivo experiments support a role of P2X7Rs in pathogenic 
neuroinflammatory features of animal models of AD. For instance, one study showed that 
P2X7Rs were overexpressed in astrocytes and microglia surrounding the A plaques in 
the Tg2576 mouse model of AD.152 A second study in APP/PS1 mice observed that 
P2X7Rs were mostly located in microglia generating excessive ROS, with ensuing 
dendritic damage. The investigators correlated these findings with A increase and 
synaptotoxicity.158 Furthermore, in the rat hippocampus injected with A1-42, a 
considerable amount of P2X7Rs colocalized with microglia.159 A similar finding was 
recently reported in P3015 mice, a model of tauopathy; in this model, P2X7Rs were 
predominantly expressed by astrocytes.160 
A study investigating the brain of AD patients showed augmented expression of P2X7Rs 
in microglia; P2X7Rs  were predominantly expressed in association with A plaques and 
localized in immunoreactive microglia. Additionally, in cultured fetal human microglia, 
A1-42 significantly elevated P2X7R expression. Furthermore, the Ca
2+ signals evoked by 
BzATP were increased in these cells and were blocked by oATP. The investigators 
proposed that P2X7Rs mediated microglial purinergic inflammatory responses in AD 
brain.159 
The proof-of-concept of P2X7Rs as a drug target for AD was tested in a study evaluating 
J20 mice transgenic for human mutant APP. In vivo inhibition of P2X7Rs with BBG 
induced a significant decrease in hippocampal amyloid plaques. This reduction correlated 
with a decrease in glycogen synthase kinase 3 activity, increasing the proteolytic 




with A1-42, BBG improved cognition and augmented dendritic spines in hippocampal 
neurons.96 Furthermore, BBG was neuroprotective and antagonized the 
neuroinflammatory responses induced by P2X7R agonists in a rat brain injected with 
A162 
 
5.3 Parkinson’s disease 
The involvement of P2X7Rs and neuroinflammation in the pathogenesis of PD has 
extensive experimental support.23 For instance, in vitro experiments revealed that ATP 
and 6-hydroxydopamine (6-OHDA) induced cytotoxicity in SN4741 dopaminergic 
neurons via activation of P2X7Rs.163 In contrast, ATP release induced by stimulation of 
SH-SY5Y cells was mediated by direct activation of P2X7Rs by -synuclein.164 Both 
postmortem analysis of brain tissue from PD patients and in vivo experiments in animal 
models of PD support the association between P2X7Rs, neuroinflammation, and loss of 
dopaminergic neurons in PD. 
Notably, P2X7Rs are upregulated in the brain of PD patients.165 This is in line with the 
supposition that excessive microglial activation and chronic neuroinflammation 
contribute to dopaminergic neuron degeneration in the substantia nigra and striatum of 
PD patients. Furthermore, the accumulation of oligomerized -synuclein is postulated to 
mediate neurotoxicity by activating microglia, followed by the production of ROS and 
pro-inflammatory mediators.166 Importantly,  -synuclein binds to P2X7Rs in microglia 
and stimulates P2X7R transcription,167 thus explaining the upregulation of P2X7Rs in PD 
brain.165 
In the brain of PD patients, notable microgliosis has been observed; this can be mimicked 
in a rat model of PD by unilateral intranigral injection of 6-OHDA, inducing DA 
depletion, nigrostriatal lesions, and microgliosis. P2X7R antagonists such as BBG or A-
438079 attenuate microgliosis and mitochondrial dysfunction, as well as motor and 
memory impairment, reinforcing that P2X7Rs take center stage in neuroinflammation and 
microglia activation in PD. 168-170 
In PD, the in vivo proof-of-concept that P2X7R blockers can protect DA neurons from 
degeneration has been investigated in several studies. For instance, using tyrosine 




neurons in rats injected with 6-OHDA.168,171 Similar neuroprotective effects of BBG have 
been demonstrated in an intranigral LPS animal model of PD, presenting marked 
reduction of activated microglia and protection of DA neurons.172 
Additionally, some reports were unable to establish the neuroprotective effects of P2X7R 
antagonists. For instance, an intranigral injection of the P2X7R antagonist, A-438079, 
attenuated DA store depletion; however, it failed to reduce the loss of DA neurons in the 
6-OHDA model of PD.170 Similarly, either deletion of P2X7Rs or their pharmacological 
inhibition failed to afford neuroprotection in the MPTP mouse model of PD.173 Despite 
these findings, overall evidence supports the hypothesis that P2X7R-elicited microglial 
activation is linked to PD pathogenesis. However, doubts persist regarding whether the 
neuroprotection conferred by P2X7R antagonists results solely from microgliosis 
inhibition, or whether derived from a direct effect on neuronal P2X7Rs. Two types of 
approaches emphasize microglia as targets for P2X7R antagonists. First, the 
immunocytochemical observations discussed above showed P2X7R expression 
colocalizing with nigrostriatal microglia in animal models of PD. Second, a recent brain 
analysis of conditional humanized P2X7R mice confirmed the expression of P2X7Rs in 
all major non-neuronal lineages throughout the brain, including microglia, astrocytes or 
oligodendrocytes; P2X7Rs were further observed in pyramidal neurons of the 
hippocampus, questioning their presence in DA neurons.174 
 
5.4 Amyotrophic lateral sclerosis 
The challenges in establishing new ALS treatments are partly attributed to the unknown 
disease pathophysiology. However, there is evidence implicating neuroinflammation and 
P2X7Rs in disease pathogenesis. The initial evidence appeared when protein levels of 
P2X7Rs were found to be upregulated in the postmortem spinal cord tissue of ALS 
patients, along with the enzyme cyclooxygenase 2 (COX-2). Expression of this enzyme 
is increased upon injury or inflammation, stimulated by the release of the pro-
inflammatory cytokines IL-1β and TNF-α, through the activation of P2X7Rs.175 In ALS, 
the relationship between P2X7R activation and motoneuron death was further established 
in co-cultures of astrocytes and motoneurons from SOD1G93A and WT mice. Repeated 




and SOD1G93A astrocytes, inducing motoneuron death prevented by treatment with 
BBG.176 
Despite these results, which suggest negative effects of P2X7Rs in ALS, genetic ablation 
of the receptor in SOD1G93A mice accelerated and worsened disease progression, inducing 
earlier disease onset177 and suggesting a dual role of the receptor in the disease, with 
protective activity at some disease stages. This dual role could be explained by the two 
different phenotypes presented by microglia upon P2X7R activation: M1 or pro-
inflammatory and M2 or anti-inflammatory. Reportedly, M2 is found to be predominant 
in the early disease stages, while M1 appears more prevalent at later stages, as observed 
in aged SOD1G93A mice.178,179  
The rationale why microglia evolve toward an M1 phenotype at a certain stage of the 
disease remains elusive. However, ALS genetics could partly explain this through the 
dysregulation of miRNA production owing to the above-mentioned mutations in FUS and 
TDP-43 genes.  Several miRNAs were found to be upregulated in SOD1G93A microglia, 
with miR-125b being the most relevant.180 The involvement of miRNA-125b in microglia 
activation toward M1 phenotype and motoneuron death was established in microglial 
primary cultures from SOD1G93A mice. Reportedly, miRNA-125b activated the NF-κB 
signaling pathway, leading to transcription of the pro-inflammatory genes TNF-α, Ncf-2, 
and NOX2. Upregulation of miRNA-125b correlated with an increase in the transcription 
and activation of P2X7Rs, which upon ATP stimulation resulted in the release of the pro-
inflammatory cytokines such as IL-1β, TNF-α, and IL-10, and further miRNA-125b 
transcription. Under normal conditions, this vicious circle of neuroinflammation would 
be controlled by the anti-inflammatory protein A20, which blocks the NF-κB signaling 
pathway. However, in ALS, microglia A20 was downregulated upon P2X7Rs stimulation 
with BzATP, contributing to the chronic neuroinflammatory environment present in 
SOD1G93A mice.179 
Furthermore, other signaling pathways are altered and implicated in the development of 
ALS, such as the NADPH oxidase (NOX) pathway, a major source of extra and 
intracellular ROS in microglia. In SOD1G93A mice, stimulation of microglial P2X7Rs with 
ATP promoted the stimulation of NOX2 and the kinase ERK1/2, which together 
provoked an increased generation of ROS.177 Additionally, P2X7Rs have been found to 




stimulation of P2X7Rs augmented autophagy markers and M2 microglial phenotype 
markers. However, persistent stimulation of the receptor resulted in impairment of the 
autophagic flux, which could correspond with the change to M1 phenotype.181 
Although these studies presented the general idea that P2X7Rs and their signaling 
pathways are upregulated in ALS patients and SOD1G93A mice, one study reported 
downregulation of the receptor and intracellular calcium dysregulation in peripheral 
blood mononuclear cells from ALS patients;182 the reason for this discrepancy has not 
been explored. In short, the P2X7R seems to display a clear involvement in the 
development and pathogenesis of ALS; hence, its role as a potential therapeutic target for 
the treatment of ALS deserves further elucidation and characterization.  Furthermore, the 
proof-of-concept supporting the hypothesis that P2X7R antagonists have therapeutic 
potential in ALS patients has been explored in a few studies. 
The use of P2X7R antagonists for ALS treatment has been evaluated in the SOD1G93A 
mouse model of the disease. Reportedly, BBG is the most explored antagonist, tested at 
different concentrations, dosing frequencies, and initiated at various stages of the disease. 
In a first study, BBG was administered intraperitoneally at a concentration of 45 mg/kg 
every 48 h, starting at the late pre-onset stage of the disease, at postnatal 90 days (P90). 
BBG treatment ameliorated motor performance deficit in treated mice, which was greater 
in males than in females; however, no effect on survival was observed.183 
As previously mentioned, P2X7Rs appeared to possess a dual role in the course of ALS, 
protective during the early stages and promoting cell death at late stages. Hence, it is 
crucial to adjust the time at which P2X7R antagonist therapy is initiated in mice. In a 
comparison between different administration start points, BBG (250 mg/kg, 3 
times/week) at late pre-onset (P100) enhanced motor neuron survival and reduced 
microgliosis in the spinal cord of SOD1G93A mice; this was not observed when treatment 
was initiated at earlier stages. In both males and females, disease onset was delayed, as 
well and motor performance was improved, although survival was not affected.98 Bartlett 
and colleagues started BBG administration (45.5 mg/kg, 3 times/week) at pre-onset or 
P62-P64, reducing body weight loss in females but not in males, as a sign of delayed 
muscle loss. Similarly, it prolonged survival in females but not males; however, motor 
performance was not affected in either sex.97 Lastly, the administration of PX7R 




BBG, failed to improve motor performance, disease onset, or survival in SOD1G93A mice 
(30 mg/kg, 5 times/week for A-804598 and 30 mg/kg, 3 times/week for JNJ-
47965567).181,184 
Collectively, P2X7R antagonists seem to exert beneficial effects in the SOD1G93A mouse 
model of ALS. However, to reveal these beneficial effects, it appears crucial that the 
starting point of treatment is adjusted, as well as the dosing and frequency of P2X7R 
antagonist administration. Moreover, chronic administration of P2X7R antagonists to 
SOD1G93A mice presented an intriguing gender difference that warrants further 
examination. Future experiments in mouse models of ALS should carefully consider the 
pharmacokinetics of brain-permeable P2X7R antagonists, focusing on a longer half-life 
and higher solubility, to allow their continuous administration either with food, drinking 
water, or sustained-release minipumps. 
 
5.5 Huntington’s disease 
The role of P2X7Rs in HD has not been extensively investigated, with only a few facts 
known about this possible relationship. In mouse and cellular models of HD, an increase 
in P2X7R levels was observed in HD neurons, as well as a dysregulation in calcium 
permeability mediated by the receptor. Moreover, mutant huntingtin-expressing neurons 
were prone to undergo apoptosis upon P2X7Rs stimulation.24 Although these results 
suggest an involvement of P2X7Rs in HD, further investigations are needed to better 
define the potential role of these receptors in disease pathogenesis.  
The proof-of-concept for the involvement of P2X7Rs in the development of HD has been 
examined only in one in vivo study performed in the R6/1 mouse model of HD. BBG 
treatment (45.5 mg/kg, every 48 h during 4 weeks) in 8-month old mice prevented body 
weight loss and improved motor coordination. However, treatment with the antagonist A-
438079 (34.2 mg/kg, every 24 h) failed to present any difference when compared with 






5.6 Multiple sclerosis 
The involvement of P2X7Rs in the pathogenesis of MS is based on postmortem 
observations, with P2X7Rs demonstrating high expression in activated microglia and 
astrocytes in the spinal cord and brains of patients.175,185 In a rat model of MS, 
experimental autoimmune encephalomyelitis (EAE),186 upregulation of P2X7Rs was 
observed in astroglia at an early asymptomatic stage187 and in neurons and 
oligodendrocytes at a later symptomatic stage.188 P2X7R deficiency suppressed the 
development of EAE.189 
Interestingly, P2X7Rs remained elevated in EAE rats even 20 days after immunization, 
correlating with sustained astrocytosis in advanced disease stages in both EAE and MS 
patients.190,191 These data are reinforced by the recent observation of increased P2X7Rs 
in frontal cortex astrocytes from patients presenting progressive MS.192 These augmented 
P2X7Rs lead to increased ATP signaling, with concomitant oligodendrocyte 
excitotoxicity and death. Moreover, a proof-of-concept of P2X7R involvement in MS 
pathogenesis is the finding that, in EAE rats, the administration of P2X7R antagonists 
(BBG or oATP) decreased astrogliosis and demyelination, thereby improving 
neurological symptoms.188,193 This supports the view that P2X7R blockers could have a 
role in preventing or improving MS symptoms.23 
 
5.7 Retinal degeneration 
The mammalian retina expresses most of the purinergic receptor subtypes, as well as the 
vesicular transporters ATP, VNUT, and the molecular machinery required for ATP 
degradation.194-196 P2X7Rs are widely expressed in several types of retinal cells (Figure 
10), including retinal pigmented epithelium (RPE), pericyte-containing retinal 
microvessels, and glial cell types such as astrocytes, microglia, and human Müller 
cells.196-201. Concerning neuronal cells, immunohistochemical studies demonstrated the 
expression of P2X7Rs in the outer plexiform layer (synaptic sites in rods and cones), 
inner nuclear layer (in horizontal and amacrine cells), inner plexiform layer, and retinal 
ganglion cells.196,200,202 A large body of studies, both in isolated cells and in retinal tissue 
samples of different animal species, support the expression of P2X7Rs in neurons, as well 
as their role in the modulation of neurotransmitter release and regulation of synaptic 




In the eye, the purinergic system has predominant roles in most physiological and 
pathological processes. Purine signaling through P2X7Rs is prominent in physiological 
processes in the lacrimal gland, cornea, trabecular meshwork, lens, RPE, and retina.200 
Purines have a modulatory role in the inner and outer retina. Functional 
electrophysiological studies have evidenced that P2X7R activation induces changes in a- 





Purinergic signaling plays a central role in the induction of retinal gliosis, as well as in 
mediating degeneration of the injured and diseased retina. Notably, stressed cells release 
large quantities of ATP. P2X7R overstimulation mediates the formation of plasma 
membrane pores contributing to cytotoxic calcium overload and cytolysis. Furthermore, 
the P2X7R pore is associated with the activation of the inflammasome, as well as the 
inflammasome-dependent cell death pathway.14 Under pathological conditions, not only 
sustained stimulation but additionally, P2X7Rs upregulation may predispose retinal 
neurons to damage. Through P2X7Rs, ATP released by neurons or glial cells can induce 
the activation and proliferation of microglia, resulting in the release of pro-inflammatory 
cytokines such as TNF- and IL-1, which can further promote microglial activation and 
the propagation of retinal gliosis from a focal injury into the surrounding non-injured 
tissue; this could induce secondary cell death in the retina207,208, worsening the 
neurodegenerative process.14,209 
It is well accepted that increased extracellular ATP and P2X7R activation play a relevant 
role in retinal degenerative diseases.210,211 As stated previously, P2X7Rs are involved in 
oxidative stress,212,213 inflammatory processes23,39, and cell death.16 In the retina, P2X7R 
activation has been related to inflammation, as well as the oxidative processes.214,215 
Hence, pharmacological modulation of purinergic receptors may have a clinical 
therapeutic impact on retinal neurodegenerative diseases.14,209,212 We next discuss how 





In developed countries, age-related macular degeneration (AMD) is the leading cause of 
severe and irreversible vision loss in the elderly.216 In this pathology, alteration of RPE 
cells, followed by photoreceptor degeneration and vascular angiogenesis is the most 
critical cause of visual impairment.209 A high concentration of ATP was observed in the 
vitreous humor of patients with AMD and vitreous hemorrhage.217 Genetic variations of 
P2X7Rs and P2X4Rs increase the risk of AMD.218 Results from in vitro and in vivo 
experiments using models mimicking dry and wet AMD demonstrated that P2X7Rs 
mediate AMD-like defects.219 In mice, the loss of function of P2X7Rs induced retinal 
changes similar to those observed in early AMD, associated with reduced phagocytosis; 
hence, this could be an important determinant in the development of AMD and/or its 
progression.220,221 P2X7Rs activation contributed to calcium signaling and apoptosis in 
RPE.222 In geographic atrophy, the late-stage of the dry form of AMD, reduced levels of 
the microRNA processing enzyme DICER1 were observed in RPE, which increased Alu 
RNA transcripts (noncoding transcripts belonging to the Alu family of retrotransposons) 
that induce cell death. In a mouse model of geographic atrophy, a relationship of increased 
Alu levels was observed following activation of P2X7Rs, and the formation of the 
inflammasome was established.223 In this study, nucleoside reverse transcriptase 
inhibitors were able to suppress the laser-induced choroidal neovascularization224 and 
prevented P2X7Rs-mediated NLRP3 inflammasome activation induced by Alu RNA; 
therefore, these inhibitors have been suggested for drug repurposing in P2X7R-driven 
diseases.225 
Diabetic retinopathy (DR) is the most common complication of diabetes and a leading 
cause of vision loss worldwide, induced by changes in retinal vascular cells.226 In diabetic 
patients, fibroblasts demonstrate a high level of ATP release or increased P2X7R 
reactivity.227 Furthermore, diabetic mice upregulate P2X7Rs in the retina and retinal 
endothelial cells,228 consistent with the fact that P2X7Rs are involved in the 
microvascular complications of DR.229 Diabetes increases the susceptibility of retinal 
microvessels to P2X7R activation, which can reduce retinal blood flow and disrupt 
vascular function in DR.230,231 Moreover, P2X7Rs are involved in the inflammatory state 
in diabetes, as Müller cells can induce the P2X7R-dependent expression of cytokines by 
microglial cells, contributing to the development of early experimental DR.232 
Glaucoma is a leading cause of vision loss, characterized by retinal ganglion cell (RGC) 




risk factors. In animal models of glaucoma, increased intraocular pressure can induce the 
release of excessive extracellular ATP in the retina and cause damage in ganglion cells 
by acting on P2X7Rs.233 Additionally, the expression of the nucleotide transporter VNUT 
is significantly increased during glaucoma progression.234 In an experimental model of 
glaucoma, degrading extracellular ATP or blocking P2X7Rs prevented acute pressure-
induced damage in ganglion cells.235 In a rat chronic ocular hypertension model, P2X7R 
antagonists protected RGC by inhibiting microglial activation.207 Alterations in 
purinergic signaling have been associated with inherited NDDs such as retinitis 
pigmentosa (RP); inhibition of P2X7R signaling delayed photoreceptor degeneration in 
rd1 mice, a model of human recessive retinitis pigmentosa211 
Both in vitro and in vivo models are being used to establish the relationship between 
P2X7Rs and the different retinal degenerative diseases. For instance, primary cultures of 
neuronal retinal cells have been used to demonstrate that P2X7R overstimulation induces 
a sustained increase in [Ca2+]c and cell death.
236-238 Primary cultures allow examining the 
protective role of P2X7R antagonists.214,236,238,239 Primary cultures of human RPE cells 
from donors have been used to demonstrate that activation of P2X7Rs induces apoptosis 
through P2X7R-mediated calcium influx.222 Cultured human retinal pericytes exposed to 
high glucose levels have been used as an in vitro model of early DR. Using this model, it 
was shown that P2X7R inhibition reverts the cytotoxic effects of high glucose.240 
To date, retinal cell lines have not been widely used to investigate purinergic signaling. 
However, several immortalized retinal cell lines have been described, such as those 
derived from ganglion cells,241 photoreceptors,242,243 Müller glia cells,244-250 astrocytes,251 
endothelial cells,252,253 perycites,254 and RPE.255 The photoreceptor-derived 661W cell 
line is a mouse photoreceptor-derived cell line, obtained from a retinal tumor formed in 
a transgenic mouse expressing SV40 large T-antigen under the control of the human IRBP 
(interphotoreceptor retinoid-binding protein) promoter.242,256 This cell line has been used 
to study cytotoxicity induced by ATP and the protective effect of substances such as 
saffron.257 Additionally, the human RPE cell line, ARPE-19, has been widely used, 
mostly as an in vitro model of AMD. Using this model, a pivotal role of P2X7R-pannexin-
1 in oxysterol toxicity has been demonstrated in retinal cells.258 The mouse ganglion cell 
line RGC-5 has been used to investigate the involvement of miR-187/P2X7R signaling 




In experiments with human retinal explants, RGC death was elicited following  P2X7R 
activation.260,261 Moreover, retinal organotypic cultures can offer a reliable system to 
study neurodegeneration and neuroprotection, as long as the in vitro architecture and 
cellular connections are maintained within the tissue262,263.  This model presents an option 
in between cell line studies and in vivo models, and has been used to demonstrate that 
P2X7R activation mediates RGC death in human retinas.260 
In different animal models of retinal diseases, several studies have demonstrated that 
through P2X7Rs, ATP is associated with cell death. To develop pharmacological 
therapies to restore visual function, animal models of retinal degeneration and blindness 
are an essential tool for proof-of-concept trials. A good model of retinal 
neurodegeneration should mimic the human degenerative process, affecting the same 
neuronal cell types involved in human pathology. Additionally, P2X7R pharmacology 
varies in different animal species, although selective and competitive P2X7R antagonists 
demonstrate fewer species differences than earlier non-selective antagonists.120 
P2X7R-deficient mice have helped demonstrate the involvement of P2X7Rs in the 
regulation of inner retinal responses of rod and cone pathways.196 Furthermore, in these 
mice, the lack of P2X7Rs induced a delayed loss of retinal ganglion cells and decreased 
phagocytic microglia after optic nerve axotomy.264 To evaluate whether P2X7Rs play a 
causative role in oxidative stress-induced AMD, P2X7R deficient mice have been cross-
bred with Sod1-deficient mice, a model of AMD. This P2X7R/Sod1 double-knockout 
demonstrated that P2X7Rs are involved in microparticle accumulation within 
RPE/choroid tissues, and play a critical role in inducing the accumulation of 
microglia/macrophages in the subretinal space.212 Furthermore, other animal models for 
AMD have been used to study the relationship of P2X7Rs with the initiation of disease 
progression in AMD, including an intravitreal injection with toxic Alu RNA transcripts 
used as a model of geographic atrophy,223 as well as laser injury to induce choroidal 
neovascularization as a model of the wet form of AMD.224 Both models have been used 
to analyze the effect of nucleoside reverse transcriptase inhibitors on P2X7R-related 
inflammation and neovascularization processes, as well as their therapeutic potential in 
AMD. In a mouse model of subretinal hemorrhage induced by an injection of autologous 
blood into the subretinal space, extracellular ATP induced an acceleration of apoptosis 




To study inherited retinal degenerative diseases, both naturally occurring and genetically 
modified mutants have been found or developed.265,266 Several mouse models carrying 
genetic mutations in the rhodopsin gene (rd), mimicking human RP hereditary disease, 
have been described.267,268 To date, these mouse models have not been extensively used 
to investigate purinergic pharmacology or its relationship with degenerative diseases. In 
BALBCrds mice, an early upregulation of neuronal P2X7Rs has been associated with 
injury and retinal damage.269 Additionally, the rd1 mouse model was used to demonstrate 
the protective effect of the purinergic antagonist PPADS on photoreceptor survival during 
the degenerative process.211 
Notably, other experimental models mimic retinal degeneration by causing toxicity and 
cell death. Intravitreal injections of ATP or Bz-ATP have been validated as models of 
degeneration; an ATP injection causes cell death and reorganization of the outer retina, 
gliosis, and progressive retinal degeneration and remodeling,211,238,270-272 which is 
common in all retinal degenerative processes.209 This effect was evident in control mice, 
but not in P2X7R deficient mice.273 The phototoxicity observed in ATP or BzATP 
injected eyes was possibly attributed to the activation of P2X7Rs on photoreceptors and 
other retinal cells, and this model allows the testing of potential therapeutic compounds 
in a relatively short period.270,273 As in glaucoma, injury to RGCs is mimicked using an 
injection of N-methyl-D-aspartate (NMDA) with hypertension models, as well as with 
injuries elicited by axotomy or optic nerve crush. P2X7R antagonists protected ganglion 
cells after the NMDA injection.274 In a rat model of chronic ocular hypertension by 
cauterizing episcleral veins, P2X7R antagonists protected RGCs by inhibiting microglial 
activation.207 Furthermore, P2X7R antagonists effectively protected RGCs after several 
insults, i.e. optic nerve injury214 or optic nerve crush.214 
As multiple cell death pathways exist, inhibition of P2X7Rs may be insufficient to 
prevent cell death in vivo, and the simultaneous inhibition of more than one death pathway 
could be necessary for efficacious neuroprotection.14 Hence, primary cultures and cell 
lines offer a useful model to investigate cell death and neuroprotective mechanisms. 
Despite extensive limitations, the well-regulated conditions afforded by these models 





6 STATE-OF-THE-ART CLINICAL TRIALS IN NEURODEGENERATIVE 
DISEASES 
Before attempting to explain the delay in access to clinical trials (CTs) investigating 
P2X7R antagonists in NDDs, we need to briefly establish previous and ongoing CTs in 
these diseases. This will clarify why P2X7R antagonists are considerably neglected in 
their logical and eventual pathway from bench to CTs. 
For instance, in AD the frame remains highly disappointing, as exemplified in two recent 
reviews. One identified 2,072 CTs in the database ClinicalTrials.gov: only 229 were fully 
published.275 The other review included 744 CTs at different phases; 80% involved drug 
investigations.276 Despite extensive efforts and enormous investment, only two classes of 
drugs, presenting mild symptomatic effects, have been introduced in clinical practice 
nearly two decades ago: cholinesterase blockers (rivastigmine, donepezil, galantamine) 
and one antagonist of glutamate NMDA receptors (i.e. memantine). A drug capable of 
modifying the natural trajectory of AD, thereby reducing its progression, is still lacking. 
In terms of AD CTs, reasons for possible failure are diverse in nature. One possible 
rationale is the mechanism of action, which has focused on at least 30 different targets277, 
indicating that the origin and pathogenesis of the disease are possibly being overlooked. 
Most drugs tested (small molecules or monoclonal antibodies) focused on the inhibition 
of A synthesis or aggregation and inhibition of GSK3, based on the fact that A and 
phospho-tau (P-tau) have been considered as the pathogenic hallmarks of AD for over 30 
years. As acetylcholine is tightly linked to learning and memory, and inhibitors of 
cholinesterase were successful, several agonists for nicotinic and muscarinic receptors 
were additionally explored. As AD progression affects synapses other than the 
cholinergic, different neurotransmitter systems were considered targets for drug 
development in AD. Growth factors, calcium channel blockers, and agents acting on 
oxidative stress and mitochondrial bioenergetics, as well as non-steroidal anti-
inflammatory drugs, have also been investigated.  
As the pathogenesis of PD implicates the degeneration of dopaminergic neurons of the 
substantia nigra pars compacta, the deposition of dopamine remains the gold standard, 
with the introduction of L-dopa nearly half-century ago. This is a symptomatic 
therapeutic strategy and as in the case of AD, several compounds designed for disease 




several decades in patients with PD. A targeted approach for new therapies includes -
synuclein aggregation, mitochondrial dysfunction, neuronal vulnerability, iron 
deposition, neuronal network alterations, neurotransmitter systems other than 
dopaminergic, and neuroinflammation 278. Some small molecules are in the pipeline in 
CTs of different pharma companies. For instance, nilotinib, a tyrosine kinase inhibitor 
approved for chronic myelogenous leukemia and behaving as a protector of dopaminergic 
neurons in MTPP models of PD, is in phase II CTs. Notably, -synuclein remains the 
most interesting target for disease modification, although limitations have been recorded 
owing to a lack of biomarkers for target engagement, tolerability, and safety. 
Inhibition of LRRK2 by small molecules such as DNL201 is another disease-modifying 
strategy in the initial phases of CTs. Calcium dyshomeostasis renders dopaminergic 
neurons more vulnerable; thus a 5-year phase III disease-modifying CT with the calcium 
channel blocker isradipine is currently ongoing in patients with early PD. Another CT is 
exploring the neuroprotective effect of the iron chelator deferiprone. Compounds 
impacting the mitochondria, as well as oxidative stress, such as pioglitazone or urate are 
under investigation. Finally, neuroinflammation targeting compounds, including the 
irreversible inhibitor of myeloperoxidase, AZD3241, or the glucagon-like peptide 1, are 
also being tested.278  
In the case of ALS, a recent review has summarized the results of more than 50 CTs 
conducted in the last 20 years since riluzole was approved.279 Antiglutamatergic 
compounds (ceftriaxone, memantine, talampanel, riluzole), antioxidants (coenzyme Q10, 
creatine, edaravone), neuroprotective compounds (dexpramipexole, olesoxime, TCH346, 
xaliproden), neurotrophic factors (brain-derived neutrophil factor (BDNF), ciliary 
neurotrophic factor (CNTF), insulin-like growth factor-1 (IGF-1)), anti-inflammatory 
compounds (celecoxib, erythropoietin, glatiramer acetate, minocycline, NP001, 
pioglitazone, valproic acid) and lithium, have been explored in CTs in patients with ALS. 
Except for riluzole and edaravone (the only two compounds approved), the clinical 
outcomes for all compounds were negative. Notably, in the case of riluzole, two out of 
three late-stage trials reported negative results; for edaravone, two out of three Phase III 
CTs also reported negative results.279 Masitinib, a tyrosine kinase inhibitor, is emerging 
as a unique compound to combat microgliosis and neuroinflammation, and prolonged 




on riluzole therapy in Phase III CT reported significant outcomes in patients treated with 
masitinib.  
A recent review has addressed the state-of-the-art CTs in HD.281. As observed with other 
NDDs, failure rates remain high.282 Only two symptomatic drugs are currently approved 
to treat HD chorea, including tetrabenazine and deutetrabenazine. Potential effective 
therapies include restoring synaptic function, reducing cellular stress, promoting support 
of trophic factors, and reducing and/or modulating neuroinflammation. During 2015-
2018, CTs investigating small molecules addressed the improved mitochondrial function 
and reduced oxidative stress (creatine, coenzyme Q10, BN82451B, ethyl 
eicosapentaenoic acid), inhibition of phosphodiesterase 10A to increase cyclic nucleotide 
signaling (PF-02545920), reduction of metal-induced aggregation of mHTT (PBT2), 
reduction of oxidative stress and increased BDNF levels (pridopidine), inhibition of 
noradrenaline and dopamine uptake (bupropion), modulation or reduction of 
neuroinflammation (laquinimod, cannabinoid mixture). Most compounds tested in 
patients with HD were well-tolerated, but showed no efficacy; only pridopidine, an 
activator of sigma-1 receptors, elicited a possible slowing of clinical progression, with 
laquinimod demonstrating a significant reduction in caudate and whole-brain atrophy, as 
well as in white matter loss of volume.281  
Although investigations involving disease-modifying therapies in NDDs have 
encountered continuous setbacks, simultaneous research in MS has been encouraging. As 
with other NDDs, MS is a heterogeneous disease with marked phenotypic clinical 
variability, as well as radiological, pathological, and genetic phenotypes. Despite these 
differences, in some forms of MS, drugs that can alter the natural disease course have 
been reported. Therapeutic agents in clinical use focus on inhibiting inflammation and 
blunting the immune system; small molecules include glatiramer acetate, fingolimod, 
teriflunomide, and dimethyl fumarate, as well as interferon and monoclonal antibodies. 
Limitations of currently available medications include serious adverse effects, drug 
affordability, and routes of administration. Presently, second-generation SP1-receptor 
modulators, siponimod, ozanimod, and ponesimod, are in late-stage development. 
Fingolimod, the first approved drug in this class, has presented important adverse effects 
such as bradycardia, reduction in atrioventricular conduction, lymphopenia, and 
leukopenia with potentially serious infections; as the new agents are more selective, 




anticipated. Near 100 CTs with agents for MS are ongoing; however, most are 
investigating approved molecules or new monoclonal antibodies.283 
 
 
7 FROM THE LAB BENCH TO CLINICAL TRIALS WITH P2X7R 
ANTAGONISTS  
In light of the preclinical research reviewed, the question emerges whether a P2X7R 
antagonist can enter CTs with a reasonable probability of positive outcomes in patients 
presenting a given NDD. This decision needs to consider several factors, including the 
polymorphic nature of P2X7Rs, the drug-likeness of newly synthesized compounds, the 
proof-of-concept with P2X7R antagonists in animal models of disease, and the state-of-
the-art of past and present CTs being conducted for the different NDDs reviewed. 
Additionally, the concept of multi-target compounds fits well in this analysis. 
Regarding drug-likeness, some compounds have been found to display an adequate PK 
profile. Additionally, concerns on safety have been clarified both preclinically and 
clinically as some CTs, although with negative outcomes, have been performed in patients 
with rheumatoid arthritis either with the AstraZeneca compound AZD9056100 or with the 
Pfizer compound CE-224,535101, showing a safe profile. A further argument in favor of 
safety is derived from the fact that P2X7Rs are activated only under inflammatory or 
tissue damage conditions in the presence of extremely high ATP concentrations; this 
poses P2X7Rs an ideal candidate target with few expected side effects,26,28,284,285 
elaborating the case for the more drug-like Janssen compounds, JNJ-54166060 and JNJ-
55308942. 
However, a note of caution has emerged from the above-mentioned CTs evaluating 
AZD9056 and CE-224,535 in patients with rheumatoid arthritis. It is puzzling that in 
these trials, while effective P2X7R antagonism was achieved, assessed by IL-1 release 
from circulating monocytes, clinical endpoints were not attained. Additional challenges 
could arise in the targeting of neuroinflammation in NDDs, as compounds need to readily 
cross the BBB and possess a prolonged residence time in brain tissues. Furthermore, as 
mentioned in Section 6, some P2X7R antagonists evaluated in rodent models of NDDs 




In addition to drug-likeness and safety, the transition from bench to patient should be 
based on the proof-of-concept of efficacy in animal models of NDDs. This has been 
detailed in Section 5, but for the present analysis, it would be practical to reexamine this 
concept. For instance, BBG afforded some positive neuroprotective outcomes in the J20 
mouse model of AD161, as well as in rats subjected to an intracerebral injection of A96,162 
Additionally, neuroprotection by BBG has been proven in three studies using animal 
models of PD;168,171,172 however, some other studies with A-438079 and other P2X7R 
antagonists have reported negative results.170,173 Two studies in the SOD1G93A mouse 
model of ALS have reported interesting positive outcomes with BBG;97,98 however, a 
negative result has also been reported with compound A-804598.181 Conversely, positive 
data with BBG were determined in the R6/1 mouse model of HD; however, this was not 
observed for compound A-438079.24 However, in a rat model of MS, positive outcomes 
were observed with P2X7R antagonists (BBG and oATP).188,193 Finally, in some in vivo 
models of retinal degeneration elicited by several insults, P2X7R antagonists protected 
ganglion cells.207,214,274 In addition to these in vivo experiments with P2X7R antagonists, 
data on the ablation of genes coding for P2X7Rs support their leading role in 
neuroinflammatory processes underlying the pathogenesis of various NDDs. Finally, 
numerous in vitro tissue and cell models have confirmed the protagonist role of P2X7Rs 
in neuroinflammation. 
Additionally, it is crucial to highlight that most studies in murine disease models to test 
the in vivo potential benefit of P2X7R antagonism have been performed with agents such 
as BBG, oATP, PPADS, suramin, or KN-62 (see Section 4). This over-reliance on 
compounds with poor PK and underappreciated off-target effects has been largely 
attributed to their ready availability and low costs. Thus, it is necessary to perform further 
studies with compounds selective for P2X7Rs, with a good PK profile,                                                                                   
and higher BBB permeability and residence time in the brain (see Section 4). 
Unfortunately, these agents are expensive for in vivo chronic administration to mouse 
disease models, or are available only from Pharmaceutical companies.  
Classically, the “one-target one-compound” paradigm has been extraordinarily successful 
across several diseases, enabling the discovery of new small molecules with therapeutic 
effects. Biologists define a key target and medicinal chemists design and synthesize a 
molecule that selectively interacts with these targets. Recently, genomic and proteomic 




signaling pathways of several diseases, including NDDs. However, during the last two 
decades, this approach has revealed limited success; this could be attributed to the fact 
that these complex cellular networks are highly buffered to prevent major changes in the 
physiological parameters under their control.286-288 Thus, in complex disorders such as 
cardiac heart failure, cancer, or NDDs, which result owing to multimolecular alterations, 
target-directed medicine is unlikely to capable of modifying disease progression. 
For a prolonged time, combination therapies have been increasingly used with reported 
success, including in AIDS treatment, secondary prevention of heart infarction, or cancer 
treatment.  During the last two decades, therapeutic success in several cancer types has 
been attributed to drug combinations tested in CTs based on complementary mechanisms 
of action. This strategy has been proven efficacy in neuroprotection, in both in vitro and 
in in vivo models of neuronal damage. For instance, the combination of sub-effective 
concentrations of drugs with antioxidant properties causes synergistic protection in SH-
SY5Y neuroblastoma cells.289 An alternative approach is the design of molecules 
possessing an affinity for two or more targets; this “multitarget-directed ligand” approach 
has been extensively investigated during the last decade but restricted to preclinical 
laboratory experiments.290-292 
Table 3 summarizes the specific and common pathogenic targets in NDDs. We propose 
the hypothesis of a dual drug approach, combining a specific disease target with a 
neuroinflammation target. In choosing the compound directed to a specific target, the 
more promising small molecule investigated so far should be selected. For instance, a 
blocker/modulator of glutamatergic receptors would be appropriate in patients with AD; 
as memantine has shown some therapeutic value at mild-moderate disease stages, this 
agent could be selected. As P2X7Rs behave as gatekeepers of neuroinflammation, a drug-
like antagonist should be chosen. Utilizing this drug combination, we seek to combat 
neuroinflammation while affording neuroprotection, by restoring calcium homeostasis. 








P2X7Rs are involved in multiple organismic physiological and pathological conditions 
in different body tissues. Their increased expression and prolonged activation owing to 
elevated ATP concentrations released during cell death or tissue injury contribute to the 
pathogenesis of NDDs. Therefore, under these conditions, ATP/P2X7R signaling 
stimulates the production of neuroinflammatory mediators, promoting a state of chronic 
inflammation, cell death, and disease progression.  
Considering the immense literature reviewed here, a new therapeutic concept seems to be 
emerging: neuroinflammation in NDDs could be combated utilizing drug-like, brain-
permeable P2X7R antagonists. Following the assertion of the  hypothesis, several points 
emerge:  
1. The presence of reactive glia and augmented inflammatory mediators is a 
common feature of all NDDs. 
2. This implies that combating neuroinflammation using a P2X7R antagonist could 
exert a therapeutic effect against all diseases. 
3. However, depending on the disease stage and type of disease, neuroinflammation 
could have beneficial or deleterious effects. 
4. Observational studies have concluded that chronically administered NSAIDs 
could be neuroprotective in some NDDs. However, CTs with NSAIDs have 
provided negative outcomes in AD and PD. 
5. The proof-of-concept in animal models of familial or sporadic NDDs is far from 
consistent: the chronic administration of a P2X7R antagonist is yet to provide a 
clear picture of efficacy. 
6. Drug-likeness of available P2X7R antagonists may vary considerably. 
7. P2X7R antagonists present variable kinetic binding characteristics, and the 
receptors themselves show great variability among mammalian species. 
This complex picture could help clarify why some CTs with P2X7R antagonists are yet 
to be been initiated in NDDs. Although there are numerous ongoing CTs with 
investigating distinct targets in various NDDs (particularly in AD), it remains perplexing 
that despite their complexities, a considerable number of available P2X7R antagonists 
fail to enter into clinical development. At this juncture, we need to question the 
consistency and strength of available preclinical data supporting the transition of 




inherent pathogenic complexity of these diseases should be best approached with drug 
combinations, presenting complementary mechanisms of action. Based on the thorough 
analysis performed in this review, we postulate that these combinations should involve a 
P2X7R antagonist to combat background neuroinflammation, along with a more selective 













Family Subtype Receptor type Endogenous 
agonist 
Function Most potent 
agonists 
Antagonists 
P2 P2X P2X1 
Ionotropic ATP 




P2X2 ATP, 2-MeSATP RB2, iso PPADS 
P2X3 ATP, 2-MeSATP TNP-ATP 
P2X4 ATP 5-BDBD 
P2X5 Permeable to Cl- ATPγS, ATP BBG 
P2X6 
Permeable to Na+, Ca2+, K+ 
- - 




Table 2 Principal pharmacodynamic (PD) and pharmacokinetic (PK) characteristics of the P2X7R antagonists summarized in this 
review. 
Under the red line is a list of all antagonists selective for P2X7R, while under the green line is a  list of blood-brain barrier (BBB)-permeable ones, 
unless otherwise indicated. 
Antagonist name PD activity PK properties Clinical trials 
oATP Irreversible  Only pharmacological tool - 
PPADS P2X selective Non-BBB permeable - 
BBG P2X selective BBB permeable - 
Suramin No P2 selective 
Antitrypanosomal drug 
GABAA antagonist 293 
Non -BBB, but circumventricular organs 
permeable 
Long half-life (around 50 days) 
- 
KN-62 mP2X7R selective 
CaM kinase II inhibitor 
Only pharmacological tool 
- 






Less potent than 2 Better properties than 2 
- 
Pyrimidine-2,4-diones (4) IC50 = 27 nM High metabolic stability 
Low cytotoxicity and cardiac toxicity 
- 
N-phenylpyrazoles (6 – 7) IC50 = 10 – 20 nM CYP3A4 inhibition - 
Pyroglutamic derivative (8) IC50 = 3.2 nM Metabolic stability 
Short half-life (1.5 h) 
- 
Imidazolone derivative (9) IC50 = 10 nM Slow microsomal clearance - 
1,2,4-triazine (11) IC50 = 1.1 µM clog P > 6 - 
CE-224,535 IC50 = 4 nM clog P = 2.9 Phase 2 – Osteoarthritis 
Phase 3 – Rheumatoid arthritis 
Adamantane-cyanoguanidine 
(14) 










Short brain half-life (75.6 m) 
Quinoline derivative (18) IC50 = 35 nM Good bioavailability - 
JNJ-47965567 hP2X7R IC50 = 5.3 nM Low brain half-life (4 - 6 h in mice) - 
JNJ-54166060 hP2X7R IC50 = 4 nM High microsomal stability 
CYP3A4 inhibition 
- 
JNJ-54175446 hP2X7R IC50 = 3 nM High metabolic stability 
High bioavailability 
No CYP3A4 inhibition 
Low off-target effects 
Phase 1 – Major depressive 
disorder 
JNJ-55308942 hP2X7R IC50 = 10 nM High water solubility 
High brain half-life (20 h in dogs) 






Table 3 Specific and common pathways involved in the pathogenesis of 
neurodegenerative diseases  (Adapted from 281) 
SPECIFIC PATHWAYS 





















Aggregates of TDP43 
and SOD1 
Motor neurons 















Post-translational protein alterations 
Mitochondrial dysfunction 
Excitotoxicity and/or Ca2+ dysregulation 
Axonal and/or neuronal damage 
Neuroinflammation and glia activation 
AD, Alzheimer’s disease; PD, Parkinson’s disease; ALS, amyotrophic lateral sclerosis; 
HD, Huntington’s disease; MS, multiple sclerosis; BDNF, brain-derived neurotrophic 







FIGURE 1 Diagrammatic representation of the molecular structure of P2X7R and its 
subunits. A) Crystal structure of the single subunit of the Ailuropoda melanoleuca 
P2X7R, as reported in the RCSB database (www.rscb.org).49 The different structural parts 
are depicted in different colors: head domain (HD) in red, upper body (UB) in cyan, lower 
body (LB) in blue, dorsal fin (DF) in yellow, left flipper (LF) in green, right flipper (RF) 
in magenta and the fluke (F) in orange. B) Schematic representation of the activation of 
the P2X7R by ATP, and the concomitant ion fluxes through the pore. C) Schematic 
representation of the top view of the P2X7R. The three ATP binding sites are in the UB, 
at the interface of two subunits. 
 
 
FIGURE 2 Activation of P2X7Rs induces interleukin (IL)-1 release by (i) K+ efflux: 
the macropore formed by P2X7R releasing K+, thereby causing the formation of the 
inflammasome complex that cleaves pro-caspase 1 into caspase-1; this results in the 
maturation of pro-IL-1 into IL-1  subsequently released into the extracellular space. 
(ii) P2X7R activation promotes intracellular Ca2+ increase, which in turn activates NF-























IL-1 transcription; next, caspase 1 catalyzes the conversion to mature IL-1 which can 
be subsequently released to the extracellular space (Adapted from 39). 
 
 
FIGURE 3 Chemical structure of first-generation P2X7R antagonists: oATP, BBG, 
PPADS, KN-62, suramin, and one of the paradigmatic adamantane-o-chlorobenzamide 









FIGURE 5 Benzylacetamides (5 – 9) from GSK and their constrained analogs (10) from 






FIGURE 6 1,2,4-triazines with P2X7R blocking properties114 
 
 
FIGURE 7 Cyanoguanidines from Abbott Laboratories (A-740003 and A-804598). 
Adamantane-cyanoguanidines and adamantane-o-chlorobenzamide adducts from 






FIGURE 8 First P2X7R antagonists developed by Janssen. 
 
 
FIGURE 9 Piperidine-fused heterocycles with improved pharmacokinetics (PK) and 






FIGURE 10 Scheme of cells expressing P2X7Rs in the mammal retina (in dark gray). 
RPE, retinal pigmented epithelium; OS, outer segment; ONL, outer nuclear layer; OPL, 
outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, 
ganglion cell layer; NFL, nerve fiber layer; R: rods; C: cones; M: Müller cells; B: bipolar 
cells; H: horizontal cells; A: amacrine cells, G: ganglion cells; m: microglial cells; a: 
astrocytes. 
 
 
